-
Je něco špatně v tomto záznamu ?
Does Pathological Complete Response after Neoadjuvant Therapy Influence Postoperative Morbidity in Rectal Cancer after Transanal Total Mesorectal Excision
M. Svoboda, V. Procházka, T. Grolich, T. Pavlík, M. Mazalová, Z. Kala
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- laparoskopie * metody MeSH
- lidé MeSH
- morbidita MeSH
- nádory rekta * chirurgie patologie MeSH
- neoadjuvantní terapie MeSH
- pooperační komplikace epidemiologie etiologie MeSH
- rektum chirurgie patologie MeSH
- retrospektivní studie MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
PURPOSE: It is still unclear if pathological complete response (pCR) after neoadjuvant chemoradiotherapy (CRT) in patients treated for rectal cancer causes worse postoperative outcomes, especially after transanal total mesorectal excision (TaTME). Worse postoperative outcomes might be an argument for an organ preserving watch and wait strategy in fragile patients and patients with comorbidities. The aim of this study is to evaluate whether patients treated for rectal cancer who had pCR to neoadjuvant therapy develop worse postoperative outcomes after TaTME than patients without complete response. METHODS: Comparative retrospective analysis (with nearest neighbor matching algorithm) of postoperative outcomes in two groups of patients, with pCR, n = 15 and without pCR (non-pCR), n = 57. All patients were operated on only by one surgical approach, TaTME, for middle and distal rectal tumors. All procedures were performed by one surgical team between 2014 and 2020 at the University Hospital Brno in Czech Republic. RESULTS: Overall morbidity was comparable between the groups (pCR group - 53.8% vs. non-pCR - 38.6%, p = 0.381). Anastomotic leak (AL) was observed in 33.3% of patients with pCR and in 17.5% of patients in the non-pCR group without statistical significance (p = 0.281). CONCLUSION: In conclusion, pathological complete response after neoadjuvant therapy does not appear to affect postoperative morbidity in rectal cancer after TaTME. Therefore, in patients with complete response who are not adherent to W&W surveillance, surgical resection can be perform without increased postoperative complications.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23017076
- 003
- CZ-PrNML
- 005
- 20231026105423.0
- 007
- ta
- 008
- 231013s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s12029-022-00826-y $2 doi
- 035 __
- $a (PubMed)35524090
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Svoboda, Martin $u Department of Surgery, Faculty of Medicine, University Hospital Brno Bohunice, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000156073450
- 245 10
- $a Does Pathological Complete Response after Neoadjuvant Therapy Influence Postoperative Morbidity in Rectal Cancer after Transanal Total Mesorectal Excision / $c M. Svoboda, V. Procházka, T. Grolich, T. Pavlík, M. Mazalová, Z. Kala
- 520 9_
- $a PURPOSE: It is still unclear if pathological complete response (pCR) after neoadjuvant chemoradiotherapy (CRT) in patients treated for rectal cancer causes worse postoperative outcomes, especially after transanal total mesorectal excision (TaTME). Worse postoperative outcomes might be an argument for an organ preserving watch and wait strategy in fragile patients and patients with comorbidities. The aim of this study is to evaluate whether patients treated for rectal cancer who had pCR to neoadjuvant therapy develop worse postoperative outcomes after TaTME than patients without complete response. METHODS: Comparative retrospective analysis (with nearest neighbor matching algorithm) of postoperative outcomes in two groups of patients, with pCR, n = 15 and without pCR (non-pCR), n = 57. All patients were operated on only by one surgical approach, TaTME, for middle and distal rectal tumors. All procedures were performed by one surgical team between 2014 and 2020 at the University Hospital Brno in Czech Republic. RESULTS: Overall morbidity was comparable between the groups (pCR group - 53.8% vs. non-pCR - 38.6%, p = 0.381). Anastomotic leak (AL) was observed in 33.3% of patients with pCR and in 17.5% of patients in the non-pCR group without statistical significance (p = 0.281). CONCLUSION: In conclusion, pathological complete response after neoadjuvant therapy does not appear to affect postoperative morbidity in rectal cancer after TaTME. Therefore, in patients with complete response who are not adherent to W&W surveillance, surgical resection can be perform without increased postoperative complications.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a rektum $x chirurgie $x patologie $7 D012007
- 650 _2
- $a neoadjuvantní terapie $7 D020360
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a nádory rekta $x chirurgie $x patologie $7 D012004
- 650 _2
- $a pooperační komplikace $x epidemiologie $x etiologie $7 D011183
- 650 _2
- $a morbidita $7 D009017
- 650 12
- $a laparoskopie $x metody $7 D010535
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Procházka, Vladimír $u Department of Surgery, Faculty of Medicine, University Hospital Brno Bohunice, Masaryk University, Brno, Czech Republic. prochazka.vladimir@fnbrno.cz $1 https://orcid.org/0000000177476072
- 700 1_
- $a Grolich, Tomáš $u Department of Surgery, Faculty of Medicine, University Hospital Brno Bohunice, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000154655879
- 700 1_
- $a Pavlík, Tomáš $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/000000017166032X
- 700 1_
- $a Mazalová, Monika $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Kala, Zdeněk $u Department of Surgery, Faculty of Medicine, University Hospital Brno Bohunice, Masaryk University, Brno, Czech Republic $1 https://orcid.org/000000034187388X
- 773 0_
- $w MED00204612 $t Journal of gastrointestinal cancer $x 1941-6636 $g Roč. 54, č. 2 (2023), s. 528-535
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35524090 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231013 $b ABA008
- 991 __
- $a 20231026105418 $b ABA008
- 999 __
- $a ok $b bmc $g 2000549 $s 1203438
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 54 $c 2 $d 528-535 $e 20220507 $i 1941-6636 $m Journal of gastrointestinal cancer $n J Gastrointest Cancer $x MED00204612
- LZP __
- $a Pubmed-20231013